These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37906803)

  • 41. Assessment of the Effect of Timing of Insulin Glargine Administration (Bedtime versus Morning) on Glycemic Control in Children with Type 1 Diabetes in Cairo, Egypt: A Single Centre Experience.
    Shamma RA; Anwar GM; Musa N; Mira MF; Abdou M
    Curr Diabetes Rev; 2023; 19(4):e110422203403. PubMed ID: 35410614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DYNAMIC: Dynamic glucose management strategies delivered through a structured education program improves time in range in a socioeconomically deprived cohort of children and young people with type 1 diabetes with a history of hypoglycemia.
    Pemberton JS; Kershaw M; Dias R; Idkowiak J; Mohamed Z; Saraff V; Barrett TG; Krone R; Uday S
    Pediatr Diabetes; 2021 Mar; 22(2):249-260. PubMed ID: 33205572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections.
    McAuley SA; Vogrin S; Lee MH; Paldus B; Trawley S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Jenkins AJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Ward GM; Jones TW; O'Neal DN;
    Diabetes Technol Ther; 2021 Jun; 23(6):460-466. PubMed ID: 33351699
    [No Abstract]   [Full Text] [Related]  

  • 44. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
    Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
    Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
    Hirsch IB; Abelseth J; Bode BW; Fischer JS; Kaufman FR; Mastrototaro J; Parkin CG; Wolpert HA; Buckingham BA
    Diabetes Technol Ther; 2008 Oct; 10(5):377-83. PubMed ID: 18715214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
    De Valk HW; Lablanche S; Bosi E; Choudhary P; Silva JD; Castaneda J; Vorrink L; De Portu S; Cohen O
    Diabetes Technol Ther; 2018 Nov; 20(11):758-766. PubMed ID: 30325656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function.
    Sherr J; Tamborlane WV; Xing D; Tsalikian E; Mauras N; Buckingham B; White NH; Arbelaez AM; Beck RW; Kollman C; Ruedy K;
    Diabetes Care; 2012 Apr; 35(4):817-20. PubMed ID: 22323414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous glucose monitoring systems in well-controlled children with type 1 diabetes mellitus.
    M Kowalczyk E; Adamczyk M; Pietrzyk J; Jastrzębska B; Szypowska A
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):151-158. PubMed ID: 34596369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes.
    Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
    Endocr J; 2020 Oct; 67(10):1055-1062. PubMed ID: 32565500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
    Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
    Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
    Gómez AM; Marín Sánchez A; Muñoz OM; Colón Peña CA
    Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.
    Mulinacci G; Alonso GT; Snell-Bergeon JK; Shah VN
    Diabetes Technol Ther; 2019 Jan; 21(1):6-10. PubMed ID: 30575413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study.
    Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M
    Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
    Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
    Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands.
    Serné EH; Roze S; Buompensiere MI; Valentine WJ; De Portu S; de Valk HW
    Adv Ther; 2022 Apr; 39(4):1844-1856. PubMed ID: 35226346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The switch from rapid-acting to concentrated regular insulin improves glucose control in type 2 diabetes patients on pump therapy: A cohort survey.
    Deberles E; Morello R; Hardouin J; Amadou C; Benhamou PY; Prévost G; Schaepelynck P; Chaillous L; Joubert M; Reznik Y
    Diabetes Metab; 2022 May; 48(3):101300. PubMed ID: 34728340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.